Integer (NYSE:ITGR) (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.
Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech. The Advanced Delivery segment focuses on drug delivery systems, including wearable injectors, pen and autoinjectors, prefilled syringes and inhalation devices. The MedTech segment serves cardiovascular, neuromodulation, diagnostic and orthopedic markets by manufacturing implantable components, surgical instruments, integrated assemblies and aftermarket services such as repair, reprocessing and technical support.
Tracing its heritage to the medical device operations of Greatbatch, Inc., the company formally rebranded as Integer in late 2014 to underscore its focus on outsourced device solutions. Integer operates manufacturing and R&D centers across North America, Europe and Asia-Pacific, supporting a global customer base from concept through post-market lifecycle management.
The company is led by President and Chief Executive Officer Robert A. Pollock, whose leadership has emphasized operational excellence and strategic growth in high-value medtech segments. Through targeted investments in advanced technology platforms and capacity expansion, Integer aims to deliver integrated solutions tailored to evolving regulatory requirements and end-user needs.
